FOXO4-DRI

FOXO4-DRI is a research-stage peptide that disrupts the interaction between FOXO4 and p53 proteins, causing senescent cells to undergo apoptosis (programmed cell death). Developed by Dr. Peter de Keizer at Erasmus University Medical Center, this synthetic peptide represents one of the most experimental approaches to targeting cellular aging [1]. Unlike traditional supplements with decades of human use, FOXO4-DRI has only been studied in laboratory and animal models.\n\nThe peptide gained attention in longevity research circles following its 2017 publication in Cell, where it demonstrated the ability to clear senescent cells in aged mice and restore some markers of youthful function [1]. Senescent cells are damaged cells that stop dividing but remain metabolically active, secreting inflammatory compounds that may contribute to age-related diseases. We emphasize that FOXO4-DRI remains purely experimental — no human safety or efficacy data exists.\n\nCurrent interest comes entirely from researchers and biohackers extrapolating from animal studies. The peptide is not approved for human consumption by any regulatory body, and its long-term effects in humans are completely unknown. Most peptide researchers we've consulted consider FOXO4-DRI among the most speculative compounds in the longevity space.